Status:

COMPLETED

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

Lead Sponsor:

AstraZeneca

Conditions:

Hypertension

Left Ventricular Hypertrophy

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hyper...

Eligibility Criteria

Inclusion

  • Hypertension with diastolic blood pressure within 95-115 mm/Hg or/and systolic blood pressure within 160-200 mm/Hg
  • Patients diagnosed as left ventricular hypertrophy by electrocardiogram

Exclusion

  • Secondary hypertension
  • History of myocardial infarction
  • Stroke within the previous 6 months

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

315 Patients enrolled

Trial Details

Trial ID

NCT00348686

Start Date

June 1 2006

End Date

June 1 2008

Last Update

April 2 2012

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Research Site

Busan, South Korea

2

Research Site

Cheonan, South Korea

3

Research Site

Cheongju-si, South Korea

4

Research Site

Chunbuk, South Korea

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP) | DecenTrialz